Nutricosmetics Market 2020 Analytical Overview, Growth Factors, Demand And Trends Forecast To 2026

 Global nutricosmetics market generated USD 4.73 billion in 2016 and is anticipated to Reach $14.12 Billion By 2026 to grow at a CAGR of 11.43% during the forecast period indicates a new report published by Polaris Market Research.

 

Nutricosmetics are supplements, that are oral based and is used for maintaining skin health that is an essential part of overall beauty of the body. One of the major factors driving the growth of global nutricosmetics market is the growing consumer awareness in case of personal care and grooming coupled with increasing disposable income. Nutricosmetics are substances which are majorly used to treat skin, hair and nail defects among others. In addition, this supplement is also used to protect the body from UV ray. Different substances which are used as nutricosmetics are vitamin C and E, beta carotene, polypodium leucotomes and tea polyphenols among others. Europe has held the largest market for nutricosmetics in 2017 and is expected to top the market over the forecast period.

 

 Get Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/nutricosmetics-market/request-for-sample

 

 Consumer preference towards grooming and a overall healthy lifestyle is expected to boost the global nutricosmetics market. On the other hand, lack of awareness and higher cost is acting as a restraint for the growth of the market in some of the developing nations. The global nutricosmetics market is segmented on the basis of product types, forms and application. In case of product types, vitamins held the largest market share in 2016 and is expected to hold the largest market share over the forecast period, followed by omega-3 fatty acids. Skin care is expected to hold the largest market share among the application segments throughout the forecast period of more than 35%. Rising consumer awareness regarding grooming and skin health coupled with busy lifestyle is having an impact on the growing skin care nutricosmetics segment. The global nutricosmetics market is segmented on the basis of product types, forms and application. In case of product types, vitamins held the largest market share in 2016 and is expected to hold the largest market share over the forecast period, followed by omega-3 fatty acids. Skin care is expected to hold the largest market share among the application segments throughout the forecast period of more than 35%. Rising consumer awareness regarding grooming and skin health coupled with busy lifestyle is having an impact on the growing skin care nutricosmetics segment.

 

Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/nutricosmetics-market/request-for-discount-pricing

 

Some of leading industry participants include Croda International Plc, Pfizer Inc., Sanofi-Aventis, Lucas-Meyer Cosmetics, BASF SE, ExcelVite, Denomega Nutritional Oils AS, GlaxoSmithKline, Isocell SA and Funtionalab Inc. among others.

 

 The demand for collagen as a nutricosmetic ingredient is expected to remain high throughout the forecast period. However, consumers are looking for some natural alternative of collagen. Due to this fact manufacturers are focusing on using vegan-friendly ingredients to produce nutricosmetics. Some of the non-animal sources been used by the manufacturers are bamboo silica, gooseberry extracts, white tea antioxidants and vegan phytoceramides among others.

 

Buy Now : https://www.polarismarketresearch.com/checkouts/3181

 

Apheresis equipment Market 2020 Analytical Overview, Growth Factors, Demand And Trends Forecast To 2026

 The Global Apheresis Equipment Market Is Anticipated To Reach Over USD 5,351.17 Million By 2026 according to a new research published by Polaris Market Research

 

An apheresis apparatus is a device which collects blood that is detached from a donor’s or patient’s body and splits up it into its several constituents such as red blood cells, platelets, plasma, and white blood cells. Depending on the purpose for apheresis, one of these constituents is collected and isolated by the equipment, while the others components are reverted to the body.

 

Polaris Market Research’s report on apheresis equipment market spans more than 90 pages and includes more than 70 tables and figures. Browse the detailed table of contents for, “By Procedure Type (Plasmapheresis, Plateletpheresis, Leukapheresis, Lymphopheresis, Erythrocytapheresis); By Application (Blood Donation, Therapeutic Purpose); By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Blood Donation Centers); By Regions (North America – U.S., Canada; Europe – Germany, UK, France, Italy, Russia; Asia-Pacific – China, India, Japan, Australia; Latin America – Brazil, Mexico; Middle East & Africa – UAE, Saudi Arabia, South Africa)]: Market size & Forecast, 2017 – 2026” on 

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/global-apheresis-equipment-market/request-for-sample

 

Some major key players in global apheresis equipment market include Haemonetics Corporation, Fresenius Kabi (Fenwal), Asahi Kasei Kuraray Medical Co. Ltd., Terumo BCT, Inc., HemaCare Corporation, Therakos, Inc. and B. Braun Melsungen AG among others.

 

Rising occurrence of blood-related ailments leading to the increase in demand for plasma and platelets is expected to serve the market as a high influence rendering driver. Moreover, the apheresis equipment market is driven by advancement in technology intended at delivering comparatively more rapid and effective results. Healthcare experts and researchers are now in the need for instruments that require minimum human involvement and institution of fully automatic apheresis equipment with improved displays is anticipated to augment the usage rates further bolstering the market growth.

 

The global apheresis equipment market is segmented on the basis of procedure type, application, end user, and geography. On the basis of procedure type, the global Apheresis Equipment Market is segmented into Plasmapheresis, Plateletpheresis, Leukapheresis, Lymphopheresis, and Erythrocytapheresis. In 2017, the Plasmapheresis is estimated to dominate the market growth. Increasing occurrence of blood-related diseases and rising demand for plasma-derived drugs are anticipated to serve as a primary growth driver of this segment. On the basis of application, the global apheresis equipment market is segmented into Blood Donation and Therapeutic Purpose. The therapeutic purpose is further categorized into Renal, Hematology, and Other Rare Diseases. On the basis of the end user, the global apheresis equipment market is segmented into hospitals, clinics, ambulatory surgical centers, and blood donation centers. On the basis of end users, the hospital segment is anticipated to dominate the market growth in 2017.

 

Get Special Discount On this Research Report : https://www.polarismarketresearch.com/industry-analysis/global-apheresis-equipment-market/request-for-discount-pricing

 

On the basis of region, the global apheresis equipment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was projected to dominate the global apheresis equipment market. The domination is majorly owing to growing healthcare spending, the existence of a high number of market players, high donor awareness levels, and relatively higher number of Research & Development movements concerning to product manufacturing and marketing accomplishments in this region. However, Asia Pacific is expected to dominate the global apheresis equipment market. Growing amount of diverse types hematological ailments in this region is the major factor boosting the growth of apheresis equipment market during the forecast period.

 

Buy now  : https://www.polarismarketresearch.com/checkouts/2661

Electric Traction Motor Market 2020 Analytical Overview, Growth Factors, Demand And Trends Forecast To 2026

 The global electric traction motors market is anticipated to reach USD 31.5 billion by 2026 according to a new study published by Polaris Market Research.

 

Electric traction motors are the most common means for powering locomotive engines in the currently developed railway industry, but with the growing need for sustainable use of energy, the advent of the application of traction motors has added to an efficient use and distribution of energy in the industry. Electric traction motors are widely being used across several geographies particularly for the routes with dense traffic such as the suburban and urban railways or the long distance high speed lines that require electric traction to obtain the speeds required for inter-city travel. This equipment cut down energy losses to an estimated figure of approximately 15% with an assumption of energy at wheel of 100%. With application of new traction chain, energy inputs in locomotives decrease from 167% to around 143% under the similar assumptions. Application of electric traction motors in railway engines result in cut in energy loss wherein for transformers it reduces from 10.3% to 7%, converters from 18.1% to 4.7%, gearbox and motor from 18.2% to 12.2%, vehicle parking 7.6% 8.4% (higher percentage value due to reduced total loses) and power house & auxiliary systems from 12.4% to 9.9%.

 

Get Sample : https://www.polarismarketresearch.com/industry-analysis/electric-traction-motor-market/request-for-sample

 

DC traction motors were conventionally the moist used types on both electric and diesel-electric rolling stock, however the contemporary power electronics has enabled application of AC motors. For most of the new engines built today, AC motor is the most preferred type. AC motors have certain advantages such as its simple for manufacturing as this type requires no mechanical contracts for its functioning, lighter compared to DC motors for equivalent amount of power. Use of modern and advanced electronics allows the AC units to be controlled efficiently to improve traction and adhesion. It can be controlled with microprocessors to a specific degree which also helps in regenerating current down to almost a stop whereas DC regeneration fades quickly at low speeds. Moreover, AC motors are more robust and easier to maintain than DC motors. These products are also being used in electric vehicles, conveyors and industrial machinery in the present industry space. It automobiles too, more than DC the AC motors has the larger share of application.

  

Asia Pacific region is expected to be the fastest growing market for production of electric traction motors over the forecast period from 2018 to 2026. Development of the industrial equipment manufacturing industry in India, Japan and especially China with its massive domestic demand figures is the major driving factors for the regions fast increasing consumption of these products in the railway engine manufacturing industry.

 

The worldwide demand for freight and passenger rail equipment including its infrastructure and related services in 2016 was estimated USD 214 billion in 2016. The increasing network of railways globally is a major factor to contribute to the increasing demand of rail equipment including the electric traction motors.

 

Get Offer : https://www.polarismarketresearch.com/industry-analysis/electric-traction-motor-market/request-for-discount-pricing

 

The Western Europe has been dominating the global market for production of these products and also in terms of exports, followed by the Asia Pacific and the U.S. in the third position. But the increasing subways and urban light railway systems and yearly increasing investment in intercity high-speed rail lines in Asia Pacific countries due to need from its growing population, manufacturing industry of these products in the region is likely to witness the fastest growth in the next eight years. Some of the leading industry participants include Weg Sa, Toshiba, Skoda Electric, NIDE, General Electric (GE), CG Power, Bosch, Siemen, Traktionssysteme Austria, Alsto and Crr.

 

Blood Cancer Drugs Market 2020 Analytical Overview, Growth Factors, Demand And Trends Forecast To 2026

 The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.

 

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

 

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

 

Download Sample copy :  https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample

 

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

 

 

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

 

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region. 

 

Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing

 

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

 

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

 

Car T Cell Therapy Market Is Driven by Strong Product Pipeline and Significant Research Activities

 The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market. The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.   

 

Request for a sample of this research Report: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

 

 

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

 

 

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

 

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

 

Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying

 

 

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

 

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

 

Read More : https://www.medgadget.com/2020/02/car-t-cell-therapy-market-worth-8-92-billion-by-2026-cagr-34-5-polaris-market-research.html

Next generation sequencing Market Growth, Statistics, By Application, Production, Revenue & Forecast To 2028

The global next generation sequencing market expected to reach US$ 25.85 billion by 2028 according to a new study by Polaris Market Research. The report “Next Generation Sequencing (NGS) Market Share, Size, Trends, Industry Analysis Report, By Application (Drug Discovery/Personalized Medicine, Genetic Screening, Diagnostics/Infectious Diseases, Agricultural & Animal Research); By Technology; By Product; By End-Use; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The global next-generation sequencing market is anticipated to grow owing to advancements in both technology and genetic data analysis through the use of bioinformatics and other computational tools. Market players are focusing on developing automated sequencers equipped with high speed and accuracy. Moreover, significant investments in start-ups causing intense competition, thereby reducing the cost of sequencing. This has also enabled increased adoption in emerging nations.

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/next-generation-sequencing-ngs-market/request-for-sample

 

The global next-generation sequencing market is fragmented based on application, technology, product, end-use, and region. In terms of application, the market is segmented into drug discovery/personalized medicine, genetic screening, diagnostics/infectious diseases, agricultural & animal research, and others.

 

The technology market segment is further divided into the whole genome, targeted sequencing & re-sequencing, whole exome, RNA sequencing, chip sequencing, de novo sequencing, and methyl sequencing. The product market segment is further divided into instruments, reagents & consumables, and services. The end-use market segment is further divided into healthcare institutions, academics, biotech & pharma firms, and others.

  

Segment Highlights

• Infectious diseases segment is estimated to hold a major share in the global next generation sequencing market, owing to increasing usage of NGS in infectious diseases. Genetic screening segment is expected to expand at highest CAGR during the forecast.
• Based on technology, the target sequencing segment is projected to constitute almost half of the market in 2028. This can be attributed to the fact that concerned sequencing technique offers cost effective approach and increased market activities.
• North America region is dominating in the global next generation sequencing market, holding almost one third of the market share throughout forecast period. Recent spike in COVID-19 deaths in the U.S. and government funded genetic studies favoured the region’s growth.
• The players including QIAGEN, Oxford Nanopore Technologies, and Thermo Fisher Scientific Inc. together held a significant market share of global next generation sequencing industry in year 2020.

Get Special Discount On this Research Report : https://www.polarismarketresearch.com/industry-analysis/next-generation-sequencing-ngs-market/request-for-discount-pricing

 

List of Key Players

• QIAGEN
• Thermo Fisher Scientific Inc.
• F Hoffman-La Roche Ltd.
• Oxford Nanopore Technologies
• Genomatix GmbH
• PierianDx
• DNASTAR, Inc.
• Eurofins GATC Biotech GmbH
• Perkin Elmer, Inc.
• BGI
• Bio-Rad Laboratories, Inc.
• Others

 

Polaris Market Research has segmented the next generation sequencing market report on the basis of application, technology, product, end-use and region

 Next Generation Sequencing, Application Outlook (Revenue – USD Million, 2016 – 2028)

• Drug Discovery/Personalized Medicine
• Genetic Screening
• Diagnostics/Infectious Diseases
• Agricultural & Animal Research
• Others

Next Generation Sequencing, Technology Outlook (Revenue – USD Million, 2016 – 2028)

• Whole Genome Sequencing
• Targeted Sequencing & Re-sequencing
• Whole Exome Sequencing
• RNA Sequencing
• Chip Sequencing
• De Novo Sequencing
• Methyl Sequencing

Next Generation Sequencing, Product Outlook (Revenue – USD Million, 2016 – 2028)

• Instruments
• Reagents & Consumables
• Services

Next Generation Sequencing, End-Use Outlook (Revenue – USD Million, 2016 – 2028)

• Healthcare Institutions
• Academics
• Biotech & Pharma Firms
• Others

Next Generation Sequencing, Regional Outlook (Revenue – USD Million, 2016 – 2028)

• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

 

 

Transcritical Co2 Market Poised for Steady Growth in the Future 2020-2026

The global transcritical CO2 market is anticipated to reach USD 22.44 billion by 2026 according to a new study published by Polaris Market Research.

 

Increasing application of transcritical CO2 in food processing industry as refrigerant is the major factor driving the product demand. It is used as a substitute for environmentally harmful refrigerants including HCFCs, CFCs, and HFCs. The development of transcritical CO2 as a refrigerant has shown potential in many applications regarding system cost and efficiency both and makes it viable for several applications that is not considered feasible. Some of the mechanism where transcritical CO2 is currently used includes heat pumps water heaters for commercial, domestic and industrial applications, refrigeration systems in supermarkets, chest freezers of ice creams, beverage coolers, water chillers for moderate climates industrial and air conditioning and refrigeration in trains and busses. 

 

Get Sample Copy : https://www.polarismarketresearch.com/industry-analysis/transcritical-co2-market/request-for-sample

 

The other under development and less commercialized systems that make use of the product include mobile heat pumps, transport refrigeration systems in containers and ships, reversible and space heating in residential heat pumps, vending machines for combined cold and hot beverages, residential and non-residential combined cooling and heating buildings, heat pumps for combined space, water heating and space heating. The requirements of the product in increasing number of application systems are expected to be the major factor driving its demand from several industries.

 

Some of leading and currently active industry participants include Shecco SPRL, Mayekawa MSG. Co., Ltd., Systems LMP, Inc., Henry Technologies, Inc. , Baltimore Aircoil Company, Inc. , Advansor A/S, Danfoss GmbH, Bitzer Kühlmaschinenbau GmbH , SCM Frigo SPA, Emerson Climate Technologies, Carnot Refrigeration Inc., Green & Cool World Refrigeration Ab, Carrier Commercial Refrigeration, and Hill Phoenix Inc.

 

Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/transcritical-co2-market/request-for-discount-pricing

 

In comparison to the traditional refrigerants, transcritical carbon dioxide has the best remarkable property of having low critical temperature of 31.1 degree Celsius. Owing to this, it leads to three discrete features of carbon dioxide in the refrigeration systems. These include that heat is rejected at supercritical pressures, keeps the pressure level quite high and during heat rejection it causes gliding of large refrigerant temperatures. These fundamental functionality advantages on application of transcritical carbon dioxide are expected to help in higher penetration of its applications sectors. Hence, with such advantages of the product and increasing application segments, the market value of TC CO2 is expected to increase over the forecast period.

 

North America was the leading regional market for consumption of transcritical CO2 refrigeration systems. U.S. was the largest contributor to product demand in 2017. Regulations concerning the limitations of refrigerants use and leakages along with directions for using TC CO2 refrigerants in supermarkets are expected to drive further product demand. The U.S. is also a leading manufacturer and exporter of heat pumps, which is yet another potential factor driving the industry. Asia Pacific is expected to be another leading player in the global scenario. The expanding regional machinery manufacturing base and growing TC CO2 enabled cooling systems is anticipated to boost product demand.

 

Buy now : https://www.polarismarketresearch.com/checkouts/1321